EANS-News: AGENNIX AG / Agennix AG Announces Talactoferrin Data to be Presented at ASCO 2011 Annual Meeting

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, June 1, 2011 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced that new data from Phase II trials in non-small
cell lung cancer and in severe sepsis with talactoferrin, an oral
biologic therapy with immunomodulatory and antibacterial properties,
will be presented at the upcoming Annual Meeting of the American
Society of Clinical Oncology (ASCO) to be held June 3-7, 2011 in
Chicago, Illinois. Talactoferrin-related presentations are as
follows:

The effect of talactoferrin on overall survival in prognostically
important NSCLC subsets in a randomized, placebo-controlled phase II
trial (abstract #7569)

• P. M. Parikh, A. Ranade, A. K. Vaid, S. H. Advani, A. Bapna, J. Zhu, Y.
Wang, P. M. Ismail, R. K. Malik
• Saturday, June 4, 2:00 PM - 6:00 PM, Hall A
• General Poster Session. - Lung Cancer - Metastatic/Non-Small Cell

Mortality reduction by talactoferrin alfa (TLF) in severe sepsis with different
types of infections (abstract #9024)
• J. Crawford, K. K. Guntupalli, N. C. Dean, P. E. Morris, R. K. Malik, J.
P. Schaumberg
• Sunday, June 5, 8:00 AM - 12:00 PM, S102
• Poster Session - Patient and Survivor Care
• Sunday, June 5, 11:30 AM - 12:30 PM, S100bc
• Poster Discussion Session - Patient and Survivor Care

About talactoferrin Talactoferrin is an oral biologic therapy with
immunomodulatory and antibacterial properties, which is being studied
for the treatment of cancer and severe sepsis. Talactoferrin has
demonstrated promising activity in randomized, double-blind,
placebo-controlled Phase II studies in NSCLC and in severe sepsis.
Two Phase III trials with talactoferrin in NSCLC are ongoing, and one
- the FORTIS-M trial - completed enrollment in March 2011. NSCLC is
one of the most common types of cancer worldwide and the most
frequent cause of cancer death. Agennix is also continuing the
development of talactoferrin for the treatment of severe sepsis and
plans to initiate a Phase II/III trial in that indication.
Talactoferrin has been shown to be very well tolerated in these
patient populations.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and
in severe sepsis. Talactoferrin is currently in Phase III clinical
trials in non-small cell lung cancer, and Agennix is also continuing
the development of this program for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing, and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix´s registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. There can be no guarantee
that the Company will move talactoferrin forward in development for
severe sepsis in a timely manner, if at all. Even if the results
from our later stage trials with talactoferrin, including the ongoing
FORTIS-M trial in non-small cell lung cancer, are considered
positive, they may not be sufficient to gain marketing approval in
the United States or any other country, and the regulatory
authorities may require additional information, data and/or further
pre-clinical or clinical studies to support approval. In such event,
there can be no guarantee that the Company will have or be able to
obtain the financial resources to conduct any such additional studies
or that such studies will yield results sufficient for approval.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future. Agennix™ is a trademark of the Agennix group.

For further information, please contact:

Barbara Mueller

Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel

Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade